Cookies: Information & Consent

We have placed cookies on your device to help make this website better. Some of the cookies we use are essential for this site to work. We also use some non-essential cookies to collect information for making reports and to help us improve the site. You will find more detailled information in our Privacy Chart.

March 2020

Banook Group welcomes Turenne Santé as new investor, alongside the management

Funds obtained will enable the European leader in cardiac safety to continue its…
Read the full post
May 2018

Webinar : Advances in cardiovascular diagnostic devices for clinical trial

Tuesday, May 29th, 2018  6:00 PM CEST (Central European Time) UTC/GMT + 2…
Read the full post
April 2017

Event Participation 2017

Banook Group will attend the following exhibitions. Let’s meet there!
Read the full post
February 2017

Cardiabase by Banook Group opens subsidiary in Montreal, Canada

Group strengthens its presence in North American market, aiming for 30% growth in…
Read the full post
March 2015

Banook Group - New branding announcement

Cardiabase/Banook Central Imaging becomes Banook Group - New branding announcement.
Read the full post
March 2014

Webinar: Imaging anti-cancer treatment response at a preclinical and clinical stage

Use of imaging in oncology clinical trials is mainly based on morphological evaluation…
Read the full post
Mission & strategy > Our strategy > Developing partnerships

Our strategy

Relying on talented women and men
Constantly enhancing our responsiveness and proximity
Implementing an optimal quality system
Developing partnerships



The Banook Group has established long-term, strong relationships with well-known academic research centers, such the Institut Gustave Roussy for Cancer Research, and the Pitié-Salpétrière University Teaching Hospital (CHU) for pharmacology. These close partnerships allow us to constantly refine our internal processes and provide high level expertise to our clients.


The privileged relationship we have built with the research teams at these institutions helps us remain at the forefront of advances in all fields, including the most innovative areas of medicine.


Over the 10 last years we have also developed strong relationships with many clinical pharmacology units, mostly in Europe. Through these long-term partnerships we have acquired a deep experience of pharmacology issues and solutions in drug development programs, particularly for cardiac safety in early phase trials (see the key word “IQ QT”).





Acquiring and analyzing clinical data is a technologically complex process. We have collaborated closely with innovative partners that have a deep and broad experience in this field. Our strong ties with these companies have helped us address the most daunting technical challenges raised by our sponsors.

The Banook Group has formed partnerships with the following expert companies:


  • Aepodia (support in drug developpement),
  • AMPS (signal processing solutions),
  • Intrasense (multimodal medical imaging),
  • Mortara (ECG devices manufacturer),
  • Phaster 1 (support in early drug development),
  • PhinC (statistics and PK modeling),
  • Vangiesbergen (medical writing).





Our philosophy – People serving Science. Science serving People – could not be better illustrated than by our commitment to research into treatments for tropical diseases, which afflict a substantial portion of people around the world. This area now represents one third of our activity. We work with academic structures specialized in this field, such as the London School of Hygiene and Tropical Medicine and the Liverpool School of Tropical Medicine. We provide services for cardiac safety evaluation in studies sponsored by nonprofit organisations, including the Medicine for Malaria Venture (MMV) and Drug for Neglected Diseases (DNDi).